GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » Price-to-Tangible-Book

Castle Biosciences (Castle Biosciences) Price-to-Tangible-Book : 1.93 (As of Apr. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Castle Biosciences Price-to-Tangible-Book?

As of today (2024-04-25), Castle Biosciences's share price is $19.30. Castle Biosciences's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $9.99. Hence, Castle Biosciences's Price to Tangible Book Ratio of today is 1.93.

The historical rank and industry rank for Castle Biosciences's Price-to-Tangible-Book or its related term are showing as below:

CSTL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.89   Med: 3.37   Max: 6.92
Current: 1.93

During the past 7 years, Castle Biosciences's highest Price to Tangible Book Ratio was 6.92. The lowest was 1.89. And the median was 3.37.

CSTL's Price-to-Tangible-Book is ranked better than
59.76% of 169 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.45 vs CSTL: 1.93

A closely related ratio is called PB Ratio. As of today, Castle Biosciences's share price is $19.30. Castle Biosciences's Book Value per Sharefor the quarter that ended in Dec. 2023 was $14.27. Hence, Castle Biosciences's P/B Ratio of today is 1.35.


Castle Biosciences Price-to-Tangible-Book Historical Data

The historical data trend for Castle Biosciences's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Castle Biosciences Price-to-Tangible-Book Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial 6.92 4.01 3.37 2.29 2.16

Castle Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.29 2.32 1.43 1.71 2.16

Competitive Comparison of Castle Biosciences's Price-to-Tangible-Book

For the Diagnostics & Research subindustry, Castle Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Castle Biosciences's Price-to-Tangible-Book Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's Price-to-Tangible-Book falls into.



Castle Biosciences Price-to-Tangible-Book Calculation

Castle Biosciences's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=19.30/9.994
=1.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Castle Biosciences Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Castle Biosciences (Castle Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
505 S. Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Executives
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Derek J Maetzold director, 10 percent owner, officer: Pres. & Chief Exec. Officer 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Ellen Goldberg director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Kristen M Oelschlager officer: Chief Operating Officer C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess officer: Chief Operating Officer C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple director C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Frank Stokes officer: Chief Financial Officer C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Tobin W Juvenal officer: Chief Commercial Officer C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff director, 10 percent owner C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii director, 10 percent owner C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc 10 percent owner C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p. 10 percent owner C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203

Castle Biosciences (Castle Biosciences) Headlines

From GuruFocus